{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T06:48:48Z","timestamp":1749451728894,"version":"3.41.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Overuse of opioids has been associated with a significant public health crisis, yet remain critical as adjunctive treatment in multiple myeloma (MM). Questions remain about the balance between the benefits to risks of ongoing opioid use, especially when the patient\u2019s myeloma is in remission. This retrospective review focuses on the association of chronic opioid use (COU) in a patient population predominantly people of color.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A cohort of 174 MM patients who received autologous stem cell transplant (ASCT) at an urban medical center were studied.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Baseline COU was observed in 52.9% of patients. COU rates and average morphine milligram equivalents (MME) per day were similar in those with and without bone disease. Previous illicit drug use was associated with a higher baseline COU. 142 (81.6%) patients received opioids during ASCT admission, while 105 (60.3%) were discharged on opioids and 72 (41.4%) met criteria for COU at 6\u00a0months. Opioid use at hospital discharge was associated with a higher 6-month COU (p\u2009=\u20090.008). COU at 6\u00a0months was independently associated with worse overall survival (p\u2009=\u20090.006).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We describe high rates of baseline COU in MM unrelated to bone disease. A number of patients started opioids during ASCT and were still taking them at 6-month follow-up visit. We demonstrate a negative association of 6-month COU on OS but not on PFS suggesting that opioid-related morbidity may play a role. These data highlight the need to test causality of opioid use on survival while simultaneously improving the management of pain in MM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09407-8","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:18:07Z","timestamp":1744355887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Persistent opioid use is associated with a shorter myeloma survival"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9559-0282","authenticated-orcid":false,"given":"Karen","family":"Sweiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria Avila","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Quigley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaily","family":"Kurzweil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaleel G.","family":"Sweis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory S.","family":"Calip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zacharie","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chukwuemeka","family":"Uzoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Ilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano","family":"Rondelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"1","key":"9407_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21\u201333","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"9407_CR2","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/leu.2010.62","volume":"24","author":"E Terpos","year":"2010","unstructured":"Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE (2010) Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 24(5):1043\u20131049","journal-title":"Leukemia"},{"issue":"5","key":"9407_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M et al (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431\u2013440","journal-title":"Lancet Oncol"},{"issue":"3","key":"9407_CR4","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","volume":"22","author":"E Terpos","year":"2021","unstructured":"Terpos E, Zamagni E, Lentzsch S, Drake MT, Garcia-Sanz R, Abildgaard N et al (2021) Treatment of multiple myeloma-related bone disease: recommendations from the bone working group of the international myeloma working group. Lancet Oncol 22(3):e119\u2013e130","journal-title":"Lancet Oncol"},{"issue":"3","key":"9407_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","volume":"71","author":"D Dowell","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R (2022) CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep 71(3):1\u201395","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"9407_CR6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1200\/JCO.22.02198","volume":"41","author":"JA Paice","year":"2023","unstructured":"Paice JA, Bohlke K, Barton D, Craig DS, El-Jawahri A, Hershman DL et al (2023) Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol 41(4):914\u2013930","journal-title":"J Clin Oncol"},{"issue":"12","key":"9407_CR7","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1002\/cncr.26146","volume":"117","author":"Q Shi","year":"2011","unstructured":"Shi Q, Smith TG, Michonski JD, Stein KD, Kaw C, Cleeland CS (2011) Symptom burden in cancer survivors 1 year after diagnosis: a report from the American cancer society\u2019s studies of cancer survivors. Cancer 117(12):2779\u20132790","journal-title":"Cancer"},{"issue":"8","key":"9407_CR8","doi-asserted-by":"publisher","first-page":"e2013605","DOI":"10.1001\/jamanetworkopen.2020.13605","volume":"3","author":"V Jairam","year":"2020","unstructured":"Jairam V, Yang DX, Verma V, Yu JB, Park HS (2020) National patterns in prescription opioid use and misuse among cancer survivors in the United States. JAMA Netw Open 3(8):e2013605","journal-title":"JAMA Netw Open"},{"issue":"7","key":"9407_CR9","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1001\/jamaoncol.2020.0799","volume":"6","author":"F Chino","year":"2020","unstructured":"Chino F, Kamal A, Chino J (2020) Incidence of opioid-associated deaths in cancer survivors in the United States, 2006\u20132016: A population study of the opioid epidemic. JAMA Oncol 6(7):1100\u20131102","journal-title":"JAMA Oncol"},{"key":"9407_CR10","doi-asserted-by":"crossref","unstructured":"van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ (2016) Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis. J Pain Symptom Manage 51(6):1070\u201390 e9","DOI":"10.1016\/j.jpainsymman.2015.12.340"},{"issue":"21","key":"9407_CR11","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1002\/cncr.30839","volume":"123","author":"R Sutradhar","year":"2017","unstructured":"Sutradhar R, Lokku A, Barbera L (2017) Cancer survivorship and opioid prescribing rates: A population-based matched cohort study among individuals with and without a history of cancer. Cancer 123(21):4286\u20134293","journal-title":"Cancer"},{"issue":"9","key":"9407_CR12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/jnci\/djz233","volume":"112","author":"V Jairam","year":"2020","unstructured":"Jairam V, Yang DX, Yu JB, Park HS (2020) Emergency department visits for opioid overdoses among patients with cancer. J Natl Cancer Inst 112(9):938\u2013943","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"9407_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381","journal-title":"J Biomed Inform"},{"issue":"24","key":"9407_CR14","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC et al (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood 127(24):2955\u20132962","journal-title":"Blood"},{"issue":"12","key":"9407_CR15","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548","journal-title":"Lancet Oncol"},{"issue":"10","key":"9407_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.15585\/mmwr.mm6610a1","volume":"66","author":"A Shah","year":"2017","unstructured":"Shah A, Hayes CJ, Martin BC (2017) Characteristics of initial prescription episodes and likelihood of long-term opioid use - United States, 2006\u20132015. MMWR Morb Mortal Wkly Rep 66(10):265\u2013269","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"9407_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/AJP.0b013e318169d03b","volume":"24","author":"M Von Korff","year":"2008","unstructured":"Von Korff M, Saunders K, Thomas Ray G, Boudreau D, Campbell C, Merrill J et al (2008) De facto long-term opioid therapy for noncancer pain. Clin J Pain 24(6):521\u2013527","journal-title":"Clin J Pain"},{"key":"9407_CR18","unstructured":"CDC. Module 6: Dosing and titration of opioids: how much, how long, and how and when to stop? [Available from: https:\/\/www-cdc-gov.proxy.cc.uic.edu\/drugoverdose\/training\/dosing\/accessible\/index.html."},{"issue":"1","key":"9407_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","volume":"8","author":"E Terpos","year":"2018","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA (2018) Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J 8(1):7","journal-title":"Blood Cancer J"},{"issue":"1","key":"9407_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","volume":"86","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O et al (2011) Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 86(1):23\u201331","journal-title":"Eur J Haematol"},{"issue":"3","key":"9407_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00277-013-1951-6","volume":"93","author":"C Konig","year":"2014","unstructured":"Konig C, Kleber M, Reinhardt H, Knop S, Wasch R, Engelhardt M (2014) Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Hematol 93(3):479\u2013484","journal-title":"Ann Hematol"},{"issue":"29","key":"9407_CR22","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","volume":"26","author":"A Chanan-Khan","year":"2008","unstructured":"Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL et al (2008) Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 26(29):4784\u20134790","journal-title":"J Clin Oncol"},{"issue":"2","key":"9407_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.bbmt.2019.10.002","volume":"26","author":"GE Georges","year":"2020","unstructured":"Georges GE, Bar M, Onstad L, Yi JC, Shadman M, Flowers ME et al (2020) Survivorship after autologous hematopoietic cell transplantation for lymphoma and multiple myeloma: Late effects and quality of life. Biol Blood Marrow Transplant 26(2):407\u2013412","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"9407_CR24","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C et al (2020) Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136(8):936\u2013945","journal-title":"Blood"},{"issue":"4","key":"9407_CR25","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/cncr.32593","volume":"126","author":"AW Roberts","year":"2020","unstructured":"Roberts AW, Fergestrom N, Neuner JM, Winn AN (2020) New-onset persistent opioid use following breast cancer treatment in older adult women. Cancer 126(4):814\u2013822","journal-title":"Cancer"},{"issue":"5","key":"9407_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","volume":"46","author":"E Boland","year":"2013","unstructured":"Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA (2013) Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manage 46(5):671\u2013680","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"9407_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/ejh.13759","volume":"108","author":"ML Danish","year":"2022","unstructured":"Danish ML, Shah MR, Lin Y, Ho JK, Copeland TM, Cooper DL (2022) Persistent opioid use in patients with multiple myeloma post-ASCT. Eur J Haematol 108(6):503\u2013509","journal-title":"Eur J Haematol"},{"issue":"3","key":"9407_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00520-014-2358-1","volume":"23","author":"S Sloot","year":"2015","unstructured":"Sloot S, Boland J, Snowden JA, Ezaydi Y, Foster A, Gethin A et al (2015) Side effects of analgesia may significantly reduce quality of life in symptomatic multiple myeloma: a cross-sectional prevalence study. Support Care Cancer 23(3):671\u2013678","journal-title":"Support Care Cancer"},{"key":"9407_CR29","doi-asserted-by":"crossref","unstructured":"Iqbal M SA, Wood C et al. (2018) Impact of depression or anxiety on opioid and benzodiazepine use in hospitalized Hematopoietic Stem Cell Transplantation (HSCT) Recipients. Blood 4852","DOI":"10.1182\/blood-2018-99-119912"},{"issue":"11","key":"9407_CR30","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.jpain.2017.06.010","volume":"18","author":"A Shah","year":"2017","unstructured":"Shah A, Hayes CJ, Martin BC (2017) Factors influencing long-term opioid use among opioid naive patients: an examination of initial prescription characteristics and pain etiologies. J Pain 18(11):1374\u20131383","journal-title":"J Pain"},{"issue":"10","key":"9407_CR31","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2105\/AJPH.2021.306431","volume":"111","author":"MR Larochelle","year":"2021","unstructured":"Larochelle MR, Slavova S, Root ED, Feaster DJ, Ward PJ, Selk SC et al (2021) Disparities in opioid overdose death trends by race\/Ethnicity, 2018\u20132019, from the healing communities study. Am J Public Health 111(10):1851\u20131854","journal-title":"Am J Public Health"},{"issue":"19","key":"9407_CR32","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.284.19.2518","volume":"284","author":"L Crawley","year":"2000","unstructured":"Crawley L, Payne R, Bolden J, Payne T, Washington P, Williams S et al (2000) Palliative and end-of-life care in the African American community. JAMA 284(19):2518\u20132521","journal-title":"JAMA"},{"issue":"14","key":"9407_CR33","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1200\/JCO.22.01413","volume":"41","author":"AC Enzinger","year":"2023","unstructured":"Enzinger AC, Ghosh K, Keating NL, Cutler DM, Clark CR, Florez N et al (2023) Racial and ethnic disparities in opioid access and urine drug screening among older patients with poor-prognosis cancer near the end of life. J Clin Oncol 41(14):2511\u20132522","journal-title":"J Clin Oncol"},{"issue":"3","key":"9407_CR34","first-page":"636","volume":"21","author":"G Deng","year":"2020","unstructured":"Deng G, Giralt S, Chung DJ, Landau H, Siman J, Li QS et al (2020) Reduction of opioid use by acupuncture in patients undergoing hematopoietic stem cell transplantation: secondary analysis of a randomized. Sham-Controlled Trial Pain Med 21(3):636\u2013642","journal-title":"Sham-Controlled Trial Pain Med"},{"key":"9407_CR35","doi-asserted-by":"publisher","first-page":"102939","DOI":"10.1016\/j.ctim.2023.102939","volume":"73","author":"O Okolo","year":"2023","unstructured":"Okolo O, Wertheim BC, Larsen A, Sweeney NW, Ahlstrom JM, Gowin K (2023) Integrative medicine in multiple myeloma and plasma cell disorders. Complement Ther Med 73:102939","journal-title":"Complement Ther Med"},{"issue":"2","key":"9407_CR36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/jha2.148","volume":"2","author":"R Banerjee","year":"2021","unstructured":"Banerjee R, Lazar AA, Dunn L, Knoche J, Lo M, Arora S et al (2021) Benzodiazepine and zolpidem prescriptions during autologous stem cell transplantation. EJHaem 2(2):276\u2013279","journal-title":"EJHaem"},{"issue":"16","key":"9407_CR37","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1200\/JCO.2013.52.5170","volume":"32","author":"E Del Fabbro","year":"2014","unstructured":"Del Fabbro E (2014) Assessment and management of chemical coping in patients with cancer. J Clin Oncol 32(16):1734\u20131738","journal-title":"J Clin Oncol"},{"issue":"6","key":"9407_CR38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1526-4637.2005.00072.x","volume":"6","author":"LR Webster","year":"2005","unstructured":"Webster LR, Webster RM (2005) Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med 6(6):432\u2013442","journal-title":"Pain Med"},{"issue":"5","key":"9407_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.5055\/jom.2014.0226","volume":"10","author":"T Jones","year":"2014","unstructured":"Jones T, Lookatch S, Grant P, McIntyre J, Moore T (2014) Further validation of an opioid risk assessment tool: the brief risk interview. J Opioid Manag 10(5):353\u2013364","journal-title":"J Opioid Manag"},{"issue":"2","key":"9407_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1533-2500.2006.00067.x","volume":"6","author":"CP Holmes","year":"2006","unstructured":"Holmes CP, Gatchel RJ, Adams LL, Stowell AW, Hatten A, Noe C et al (2006) An opioid screening instrument: long-term evaluation of the utility of the pain medication questionnaire. Pain Pract 6(2):74\u201388","journal-title":"Pain Pract"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09407-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09407-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09407-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T08:18:47Z","timestamp":1747901927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09407-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["9407"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09407-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"18 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no financial interests. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interests"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. We consulted with the IRB of University of Illinois who determined that our study did not need ethical approval. An IRB official waiver of ethical approval was granted from the IRB of University of Illinois.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"374"}}